Dna X (SONM) Liabilities and Shareholders Equity (2018 - 2026)

Dna X has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $4.8 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 86.55% year-over-year to $4.8 million; the trailing twelve-month figure through Mar 2026 stood at $125.0 million (down 26.76% YoY), and the FY2025 full-year result was $43.9 million, up 10.47% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $4.8 million, down from $43.9 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $58.6 million in Q3 2023, with the low at $4.8 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $43.2 million across 5 years, with a median of $43.9 million in 2025.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity surged 44.11% — and 2026, when it plunged 86.55%.
• Dna X's Liabilities and Shareholders Equity stood at $53.7 million in 2022, then climbed by 4.39% to $56.0 million in 2023, then fell by 29.09% to $39.7 million in 2024, then climbed by 10.47% to $43.9 million in 2025, then sank by 88.98% to $4.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $4.8 million (Q1 2026), $43.9 million (Q4 2025), and $40.2 million (Q3 2025), per Business Quant data.